MeiraGTx (MGTX) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Solid Biosciences (SLDB) has outperformed MeiraGTx (MGTX) over the past year, gaining 33.0% versus a gain of 7.0%. Over five years, MGTX leads with a -55.5% price change compared with -77.8% for SLDB. MeiraGTx is the larger company by market cap ($779.9 million vs $697.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | SLDB |
|---|---|---|
| Share price | $7.98 | $6.25 |
| Market cap | $779.89M | $697.57M |
| 1-day change | -1.97% | -2.95% |
| YTD return | +0.38% | +10.82% |
| 1-year return | +6.97% | +32.98% |
| 5-year return | -55.54% | -77.78% |
| P/E ratio (TTM) | 9.17 | — |
| EPS (TTM) | $0.87 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $81.39M | — |
| Revenue growth (YoY) | +144.57% | — |
| Net income (latest FY) | $-114.20M | $-174.32M |
| Operating margin | -130.20% | — |
| Net margin | -140.31% | — |
| 52-week high | $15.35 | $11.45 |
| 52-week low | $6.62 | $4.65 |
| Distance from 52-week high | -48.01% | -45.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +247.74% | +199.36% |
| Average volume | 837.25K | 1.30M |
| Shares outstanding | 97.73M | 111.61M |
| Employees | 386 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed MGTX by 26.0 percentage points over the past year.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
MGTX vs SLDB FAQ
Which is bigger, MeiraGTx or Solid Biosciences?
MeiraGTx (MGTX) is larger, with a market capitalization of $779.89M compared with $697.57M for Solid Biosciences (SLDB).
Which stock has performed better over the past year, MGTX or SLDB?
SLDB returned +32.98% over the past 12 months, compared with +6.97% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.